Literature DB >> 10358165

Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats.

A Saoudi1, I Bernard, A Hoedemaekers, B Cautain, K Martinez, P Druet, M De Baets, J C Guéry.   

Abstract

Experimental autoimmune myasthenia gravis (EAMG) is a T cell-dependent, Ab-mediated autoimmune disease induced in rats by a single immunization with acetylcholine receptor (AChR). Although polarized Th1 responses have been shown to be crucial for the development of mouse EAMG, the role of Th cell subsets in rat EAMG is not well established. In the present work we show that while the incidence and severity of EAMG are similar in Lewis (LEW) and Brown-Norway (BN) rats, strong differences are revealed in the immune response generated. Ag-specific lymph node cells from LEW rats produced higher amounts of IL-2 and IFN-gamma than BN lymph node cells, but expressed less IL-4 mRNA. IgG1 and IgG2b anti-AChR isotype predominated in BN and LEW rats, respectively, confirming the dichotomy of the immune response observed between the two strains. Furthermore, although IL-12 administration or IFN-gamma neutralization strongly influenced the Th1/Th2 balance in BN rats, it did not affect the disease outcome. These data demonstrate that a Th1-dominated immune response is not necessarily associated with disease severity in EAMG, not only in rats with disparate MHC haplotype but also in the same rat strain, and suggest that in a situation where complement-fixing Ab can be generated as a consequence of either Th1- or Th2-mediated T cell help, deviation of the immune response will not be an adequate strategy to prevent this Ab-mediated autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10358165

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.

Authors:  Jie Luo; Alexander Kuryatov; Jon M Lindstrom
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

2.  Enhanced glucocorticoid receptor signaling in T cells impacts thymocyte apoptosis and adaptive immune responses.

Authors:  Jens van den Brandt; Fred Lühder; Kirsty G McPherson; Katrien L de Graaf; Denise Tischner; Stefan Wiehr; Thomas Herrmann; Robert Weissert; Ralf Gold; Holger M Reichardt
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

3.  Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.

Authors:  M Paas-Rozner; M Dayan; Y Paas; J P Changeux; I Wirguin; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

4.  Enhanced antigen-specific delayed-type hypersensitivity and immunoglobulin G2b responses after oral administration of viable Lactobacillus casei YIT9029 in Wistar and Brown Norway rats.

Authors:  R de Waard; J Garssen; J Snel; G C Bokken; T Sako; J H Veld; J G Vos
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

5.  In the rat, citrullinated autologous fibrinogen is immunogenic but the induced autoimmune response is not arthritogenic.

Authors:  V Duplan; C Foulquier; C Clavel; R Al Badine; G Serre; A Saoudi; M Sebbag
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

6.  Granulomatous and cytokine responses to pulmonary Cryptococcus neoformans in two strains of rats.

Authors:  M Kobayashi; M Ito; K Sano; M Koyama
Journal:  Mycopathologia       Date:  2001       Impact factor: 2.574

7.  The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.

Authors:  M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

8.  Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile.

Authors:  Huan Yang; Yong Zhang; Minghua Wu; Jing Li; Wenbin Zhou; Guiyuan Li; Xiaoling Li; Bo Xiao; Premkumar Christadoss
Journal:  Inflamm Res       Date:  2009-09-19       Impact factor: 4.575

9.  Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats.

Authors:  Rui-Sheng Duan; Hans Link; Bao-Guo Xiao
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

10.  Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis.

Authors:  Lili Mu; Bo Sun; Qingfei Kong; Jinghua Wang; Guangyou Wang; Shujuan Zhang; Dandan Wang; Yumei Liu; Yixi Liu; Huixia An; Hulun Li
Journal:  Immunology       Date:  2009-03-23       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.